JP2022523726A5 - - Google Patents
Info
- Publication number
- JP2022523726A5 JP2022523726A5 JP2021544518A JP2021544518A JP2022523726A5 JP 2022523726 A5 JP2022523726 A5 JP 2022523726A5 JP 2021544518 A JP2021544518 A JP 2021544518A JP 2021544518 A JP2021544518 A JP 2021544518A JP 2022523726 A5 JP2022523726 A5 JP 2022523726A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- compound
- pharmaceutically acceptable
- hiv infection
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962799800P | 2019-02-01 | 2019-02-01 | |
| US62/799,800 | 2019-02-01 | ||
| PCT/IB2020/050743 WO2020157692A1 (en) | 2019-02-01 | 2020-01-30 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523726A JP2022523726A (ja) | 2022-04-26 |
| JP2022523726A5 true JP2022523726A5 (enExample) | 2023-01-26 |
Family
ID=69528890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544518A Ceased JP2022523726A (ja) | 2019-02-01 | 2020-01-30 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220105096A1 (enExample) |
| EP (1) | EP3917930B1 (enExample) |
| JP (1) | JP2022523726A (enExample) |
| AR (1) | AR117920A1 (enExample) |
| ES (1) | ES2941240T3 (enExample) |
| PT (1) | PT3917930T (enExample) |
| TW (1) | TW202045502A (enExample) |
| UY (1) | UY38559A (enExample) |
| WO (1) | WO2020157692A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541055B2 (en) | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| BR112021025655A2 (pt) * | 2019-06-19 | 2022-02-01 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| EP4066839A4 (en) | 2019-11-28 | 2023-12-27 | Shionogi & Co., Ltd | PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS |
| JP7703538B2 (ja) * | 2019-12-09 | 2025-07-07 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルを含んでなる医薬組成物 |
| KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| BR112022020933A2 (pt) * | 2020-04-15 | 2022-12-06 | Viiv Healthcare Uk No 5 Ltd | Inibidores de replicação do vírus da imunodeficiência humana |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121335877A (zh) | 2023-06-15 | 2026-01-13 | Viiv保健英国第五有限公司 | 用于制备化合物的方法和中间体 |
| TW202547514A (zh) | 2024-02-05 | 2025-12-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| AU2014340110B2 (en) | 2013-10-24 | 2018-07-12 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2016172425A1 (en) | 2015-04-23 | 2016-10-27 | Viiv Healthcare (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US10221129B2 (en) | 2015-04-23 | 2019-03-05 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
-
2020
- 2020-01-29 UY UY0001038559A patent/UY38559A/es not_active Application Discontinuation
- 2020-01-30 TW TW109102689A patent/TW202045502A/zh unknown
- 2020-01-30 AR ARP200100242A patent/AR117920A1/es not_active Application Discontinuation
- 2020-01-30 JP JP2021544518A patent/JP2022523726A/ja not_active Ceased
- 2020-01-30 WO PCT/IB2020/050743 patent/WO2020157692A1/en not_active Ceased
- 2020-01-30 EP EP20704596.4A patent/EP3917930B1/en active Active
- 2020-01-30 PT PT207045964T patent/PT3917930T/pt unknown
- 2020-01-30 ES ES20704596T patent/ES2941240T3/es active Active
- 2020-01-30 US US17/425,796 patent/US20220105096A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523726A5 (enExample) | ||
| DK168514B1 (da) | Synergistisk produkt indeholdende en kombination af amantadin og selegilin, fremgangsmåde til fremstilling af produktet og anvendelse af amantadin og selegilin til fremstilling af produktet | |
| JP2022537047A5 (enExample) | ||
| JP2022531251A5 (enExample) | ||
| JP2023535744A5 (enExample) | ||
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| JP2013536837A5 (enExample) | ||
| JP2022551691A5 (enExample) | ||
| US20040152625A1 (en) | Method for improving the pharmacokinetics of an NNRTI | |
| JP2016505050A5 (enExample) | ||
| JP2022553888A5 (enExample) | ||
| EP3833378B1 (en) | Treatment of warts | |
| US20030166696A1 (en) | Pramipexole for the treatment of HIV dementia | |
| IL319451A (en) | HIV treatment with CABOTEGRAVIR and RILPIVIRINE in pediatric patients | |
| KR20230015320A (ko) | 감염성 질환의 치료에서의 부실라민의 용도 | |
| CN110279691A (zh) | 一种外科术后护理镇痛药物及其用途 | |
| Shahani et al. | Status of chloroquine and hydroxychloroquine in COVID-19 infection | |
| CN104117065B (zh) | 一种基于青藤碱的用于镇痛的药物组合产品 | |
| JP2023507764A5 (enExample) | ||
| JP2024518455A5 (enExample) | ||
| CN117257790A (zh) | 芹菜素在制备用于治疗银屑病的药物中的应用 | |
| AL IDRISSI et al. | Chloroquineand hydroxychloroquine in covid 19: asystematic review | |
| UA144734U (uk) | Спосіб лікування вірусних інфекційних захворювань | |
| TW202615093A (zh) | 再使用於已中止免疫檢查點抑制劑給藥之癌症患者之免疫檢查點抑制劑的治療效果提高用醫藥 |